"New Outcomes Data for Type 2 Diabetes" is the subject of a breakfast continuing education program that will be held in Chicago on Thursday, Oct. 5. The session, hosted by Drug Topics and Formulary magazines, will examine the implications of new diabetes research and will also look at the need for tighter glucose control to minimize complications as well as the economic impact of early intervention for patients at risk for Type 2 diabetes.
"New Outcomes Data for Type 2 Diabetes" is the subject of a breakfast continuing education program that will be held in Chicago on Thursday, Oct. 5. The session, hosted by Drug Topics and Formulary magazines, will examine the implications of new diabetes research and will also look at the need for tighter glucose control to minimize complications as well as the economic impact of early intervention for patients at risk for Type 2 diabetes. The session will feature Frank Kennedy, M.D., of the Mayo Clinic College of Medicine, and Andrew Selwyn, M.D., of Harvard Medical School. To register for the event, visit: http://apps.redidata.com/diabetes/.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.